jinyizhang688@gmail.com、zhangjinyi@ojlab.ac.cn
1987-1990 Air Force Medical University PhD
1984-1987 Air Force Medical University Master
1979-1984 Air Force Medical University Bachelor
2022.10--present Professor Oujiang Lab
2022.10- present Professor School of Ophthalmology & Optometry, School of Biomedical Engineering, WMU
2017.01-2022.10 Professor Jinzhou Medical University
2011.01-2016.12 Senior Staff Scientist Lunenfeld-Tanenbaum Research Institute, University of Toronto
2004.6-2010.12 Assistant Professor Department of Medicine, University of Toronto
1999.1-2004.6 Research AssociateDepartment of Medicine, Department of Immunology，University of Toronto，Lunenfeld-Tanenbaum Research Institute
1995.1-1999.1 Postdoctoral Fellow Lunenfeld-Tanenbaum Research Institute
1994.1-1995.1 Postdoctoral Fellow University of Toronto
1993.1-1994.1 Postdoctoral Fellow CatholicUniversity of Louvain
1991.6-1993.1 Lecturer Air Force Medical University
Prof. Jinyi Zhang and his team have been answering key questions in the field of the pathogenesis of autoimmune diseases and immunotherapy. Over the past five years, he has concentrated on the development and translational research of novel therapeutic immune cell therapies. He has published over 60 articles in academic journals including Science and Nature Genetics. As principal investigator, he has secured multiple national and provincial research grants.
His research interest include:
1. Cell therapy;
2. Pathogenesis of autoimmune diseases and immunotherapy.
2017 Zhejiang Province Overseas High-Level Talent Recruitment Program
2000–2002 Canadian Rheumatism Association Rheumatism Scholarship
1996–1997 University of Toronto Postdoctoral Fellowship
1993–1994 European Community Marie Curie Fellowship
1. Wen Lei, Ai Zhao, Hui Liu, Chunmei Yang, Cheng Wei, Shanshan Guo, Zhilu Chen, Qunyi Guo, Linjie Li, Mingzhe Zhao, Gongqiang Wu, Liu Ming, Demin Duan, Jinyi Zhang*, Jimin Gao*, Wenbin Qian*. Safety and Feasibility of Anti-CD19 CAR T Cells Expressing Inducible IL-7 and CCL19 in Patients with Relapsed or Refractory Large B-cell Lymphoma. cell discovery. 2024 Jan 9; s41421-023-00625-0.
2. Liu Ming, Zhang Jinyi(co-first), Pinder Benjamin D., Liu Qingquan, Wang Dingyan, Yao Hao, Gao Yubo, Toker Aras, Gao Jimin, Peterson Alan, Qu Jia, Siminovitch Katherine A. WAVE2 suppresses mTOR activation to maintain T cell homeostasis and prevent autoimmunity. Science. 2021 Mar 26; science.aaz4544.
3. Jinyi Zhang, Naima Zahir, Qiuhong Jiang, Helen Miliotis, Stephanie Heyraud, Xianwang Meng, Baoxia Dong, Gang Xie, Frank Qiu, Zhenyue Hao, Christopher A McCulloch, Edward C Keystone, Alan C Peterson, Katherine A Siminovitch. The autoimmune disease-associated Lyp/Pep variant promotes calpain-mediated Lyp/Pep degradation, associated with reduced Lyp/Pep levels and T and dendritic cell hyperresponsiveness. Nat Genet. 2011 Aug 14; ng.904.
4. Yan Leng, Jinyi Zhang(co-first), Karen Badour, Enrico Arpaia, Spencer Freeman, Pam Cheung, Michael Siu, Katherine Siminovitch. Abelson-interactor-1 promotes WAVE2 membrane translocation and Abelson-mediated tyrosine phosphorylation required for WAVE2 activation. Proc Natl Acad Sci U S A. 2005 Jan 25; pnas.0409120102.
5. Jinyi Zhang, Fabio Shi, Karen Badour, Yupu Deng, Mary K. H. McGavin, Katherine A.
Siminovitch. WASp verprolin homology, cofilin homology, and acidic region domain-mediated actin polymerization is required for T cell development. Proc Natl Acad Sci USA. 2002 Feb 19; pnas.042686099.
6. Jinyi Zhang, Amro Shehabeldin, Luis A.G. da Cruz, Jeffrey Butler, Ally-Khan Somani, Mary McGavin, Ivona Kozieradzki, Antonio O. dos Santos, Andras Nagy, Sergio Grinstein, Josef M. Penninger, Katherine A. Siminovitch. Antigen receptor-induced activation and cytoskeletal rearrangement are impaired in Wiskott-Aldrich syndrome protein-deficient lymphocytes. J Exp Med. 1999; jem.190.9.1329.
